이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Shanghai Junshi Biosciences 관리

관리 기준 확인 2/4

Shanghai Junshi Biosciences' CEO는 Cong Li, Nov2021 에 임명되었습니다 의 임기는 2.58 년입니다. 총 연간 보상은 CN¥ 4.22M, 100% 로 구성됩니다. 100% 급여 및 0% 보너스(회사 주식 및 옵션 포함). 는 HK$ 3.42M 가치에 해당하는 회사 주식의 0.013% 직접 소유합니다. 3.42M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 6 년입니다.

주요 정보

Cong Li

최고 경영자

CN¥4.2m

총 보상

CEO 급여 비율	100.0%
CEO 임기	2.6yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Jun 28

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

May 06

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Mar 22

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Jan 26

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Dec 17

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Nov 20

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Sep 05

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

May 22

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

May 01

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Jan 16

Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 03

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Oct 12

CEO 보상 분석

Cong Li 의 보수는 Shanghai Junshi Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥4m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥2b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥3b
Dec 31 2022	CN¥4m	CN¥4m	-CN¥2b

보상 대 시장: Cong 의 총 보상 ($USD 581.18K )은 Hong Kong 시장( $USD 446.31K ).

보상과 수익: 회사가 수익성이 없는 동안 Cong 의 보상이 증가했습니다.

CEO

Cong Li (60 yo)

2.6yrs

테뉴어

CN¥4,224,000

보상

Mr. Cong Li has been Co-Chief Executive Officer and Executive Director at Shanghai Junshi Biosciences Co., Ltd. since November 2, 2021 and served as Non-Executive Director since December 22, 2016 until Nov...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jun Xiong	Executive Chairman	9.3yrs	CN¥8.50m	13.09% CN¥ 3.5b
Cong Li	Co-CEO & Executive Director	2.6yrs	CN¥4.22m	0.013% CN¥ 3.4m
Jianjun Zou	GM, CEO & Executive Director	less than a year	CN¥5.86m	데이터 없음
Ning Li	Executive Vice-Chairman of the Board	6yrs	CN¥9.93m	0.0051% CN¥ 1.3m
Baohong Xu	Financial Director	3.6yrs	CN¥2.73m	0.00071% CN¥ 187.9k
Zhuobing Zhang	Deputy GM & Executive Director	no data	CN¥8.13m	0.88% CN¥ 232.4m
Sheng Yao	Senior VP & Executive Director	no data	CN¥8.01m	데이터 없음
Gang Wang	Deputy GM	4.8yrs	CN¥1.32m	0.0010% CN¥ 269.9k
Xin Li	Executive Director	less than a year	데이터 없음	0.0096% CN¥ 2.6m
Lu Yuan	Assistant to GM & Chief of Internal Audit Department	3.6yrs	데이터 없음	데이터 없음
Qian Wei	Chief Commercial Officer	2.9yrs	데이터 없음	데이터 없음
Patricia Keegan	Chief Medical Officer	no data	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: 1877 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jun Xiong	Executive Chairman	9.3yrs	CN¥8.50m	13.09% CN¥ 3.5b
Cong Li	Co-CEO & Executive Director	7.5yrs	CN¥4.22m	0.013% CN¥ 3.4m
Jianjun Zou	GM, CEO & Executive Director	2yrs	CN¥5.86m	데이터 없음
Ning Li	Executive Vice-Chairman of the Board	6yrs	CN¥9.93m	0.0051% CN¥ 1.3m
Zhuobing Zhang	Deputy GM & Executive Director	7.5yrs	CN¥8.13m	0.88% CN¥ 232.4m
Sheng Yao	Senior VP & Executive Director	7.5yrs	CN¥8.01m	데이터 없음
Gang Wang	Deputy GM	less than a year	CN¥1.32m	0.0010% CN¥ 269.9k
Xin Li	Executive Director	less than a year	데이터 없음	0.0096% CN¥ 2.6m
Yi Tang	Non-Executive Director	9.1yrs	데이터 없음	0.74% CN¥ 195.7m
Chun Zhang	Independent Non-Executive Director	4yrs	CN¥200.00k	데이터 없음
Xiaoyuan Feng	Independent Non-Executive Director	2.5yrs	CN¥200.00k	데이터 없음
Hongyan Kuang	Chairman of the Board of Supervisors	no data	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 1877 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

Shanghai Junshi Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Recent updates

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

New minor risk - Shareholder dilution

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116

Now 26% undervalued

Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab

Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration

No longer forecast to breakeven